No-effect level in the mutagenic activity of the drug cyproterone acetate in rat liver: Part II. Multiple dose treatment

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 550, Issue 1-2, 2004, Pages 101-108

  Topinka, Jan ^a,b   Oesterle, Doris ^a   Reimann, Roland ^c   Wolff, Thomas ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^c BAYER PHARMA AG   (Germany)

Author keywords

area under curve; AUC; Cyproterone acetate; DNA adducts; gas chromatography coupled with mass spectrometry; GC MS; Mutations; No effect level; Transgenic rats

Indexed keywords

CYPROTERONE ACETATE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA ADDUCT; DNA ISOLATION; DRUG RESPONSE; FEMALE; GENE MUTATION; LIVER; LIVER CELL; LIVER TOXICITY; MITOGENESIS; MULTIPLE DRUG DOSE; MUTAGENESIS; MUTAGENIC ACTIVITY; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CYPROTERONE ACETATE; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIVER; MUTAGENS; MUTATION; RATS; RATS, INBRED F344; S PHASE; TIME FACTORS;

EID: 2342654438     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.02.002     Document Type: Article

References (16)

1. Mirsalis J. Dosing regimens for transgenic animal mutagenesis assays. Environ. Mol. Mutagen. 21:1993;118-119
2. Heddle J.A., Dean S., Nohmi T., Boerrigter M., Casciano D., Douglas G.R., Glickman B.W., Gorelick N.J., Mirsalis J.C., Martus H.-J., Skopek T.R., Thybaud V., Tindall K.R., Yajima N. In vivo transgenic mutation assays. Environ. Mol. Mutagen. 35:2000;253-259
3. Tao K.S., Heddle J.A. The accumulation and persistence of somatic mutations in vivo. Mutagenesis. 9:1994;187-191
4. Zhang X.B., Felton J.S., Tucker J.T., Urlando C., Heddle J.A. Intestinal mutagenicity of two carcinogenic food mutagens in transgenic mice: 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine amino(α)carboline. Carcinogenesis. 17:1996;2259-2265
5. Favor J. The mutagenic activity of ethylnitrosourea at low doses in spermatogonia of the mouse as assessed by the specific locus test. Mutat. Res. 405:1998;221-226
6. Werner S., Topinka J., Wolff T., Schwarz L.R. Accumulation and persistence of DNA adducts of the synthetic steroid cypproterone acetate in rat liver. Carcinogenesis. 16:1995;2369-2372
7. Kuhnz W., Staks T., Jütting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. Contraceptions. 48:1993;557-575
8. Schulte-Hermann R., Hoffmann V., Parzefall W., Kallenbach M., Gerhard A., Schuppler J. Adaptive response of rat liver to the gestagen and antiandrogen cyproterone acetate and other inducers. II. Induction of growth. Chem. Biol. Interact. 31:1980;287-300
9. Werner S., Kunz S., Beckurts T., Heidecke C.-D., Wolff T., Schwarz L.R. Formation of DNA adducts by cyproterone acetate and some structural analogues in primary cultures of human hepatocytes. Mutat. Res. 395:1997;179-187
10. Werner S., Kunz S., Wolff T., Schwarz L.R. The steroidal drug cyproterone acetate is activated to DNA-binding metabolites by sulfonation. Cancer Res. 56:1996;4391-4397
11. B. Schäfer, Thesis, Technische Universität München, 2000.
12. 32P postlabeling technique Pharmacol. Toxicol. 78:1996;214-223
13. Parzefall W., Erber E., Sedivy R., Schulte-Hermann R. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promotors. Cancer Res. 51:1991;1143-1147
14. Heinemann L.A.J., DoMinh T., Guggenmoos-Holzmann I., Thiel C., Garbe E. Oral contraceptives and liver cancer. Results of the multicentre international liver tumour study (MILTS). Contraception. 56:1997;275-284
15. Heinemann L.A.J., Will-Shahab L., Van Kesteren P., Gooren L.J.G. Safety of cyproterone acetate: report of active surveillance. Pharmacoepidemiol. Drug Safety. 6:1997;169-178
16. Watanabe S., Cui Y., Tanae T., Fujimoto M., Matsuo Y., Tachibana K., Yamasaki S. Follow-up study of children with precocious puberty treated with cyproterone acetate. Ad hoc Committee for CPA. J. Epidemiol. 7:1997;173-178